Cancer Targeted Therapy Market Outlook: Robust Pipeline of Monoclonal Antibodies to Drive Market Growth to US$ 235.68 Billion by 2031

As per the latest market research by Business Market Insights (BMI), the research report "Cancer Targeted Therapy Market Outlook Size and Forecast (2021–2031)" forecasts how the market is set to surge 147.8% by 2031 as strong pipeline of monoclonal antibodies reshapes the cancer targeted therapy ecosystem. The report highlights advancements in genomic profiling, revolutionizing the global landscape of cancer targeted therapy.

The report forecasts the market to expand from US$ 95.12 Billion in 2024 to US$ 235.68 Billion, registering a robust CAGR of 13.84% over the 2025–2031 period.

Advancements in genomic profiling are profoundly shaping the cancer targeted therapy market by enabling a deeper understanding of the molecular drivers behind tumor growth and progression. Genomic profiling allows clinicians to identify specific mutations, gene expressions, and signalling pathways that are unique to each patient’s cancer, thereby facilitating the development and use of therapies tailored to those genetic abnormalities. This precision approach has transformed oncology from a generalized treatment model to one that is highly individualized, improving efficacy while minimizing toxicity. The ability to detect actionable biomarkers has accelerated the approval of tumor‑agnostic therapies, which target genetic mutations across multiple cancer types rather than being limited to a single organ site. Moreover, genomic profiling supports the design of combination regimens, where targeted therapies are paired with immunotherapies or chemotherapy to overcome resistance mechanisms and enhance patient outcomes. Pharmaceutical companies are leveraging these insights to expand their pipelines, focusing on monoclonal antibodies, tyrosine kinase inhibitors, and next‑generation therapies that directly address genetic alterations. As genomic technologies become more accessible and cost‑effective, their integration into routine clinical practice is expected to broaden patient eligibility for targeted therapies, driving market growth and setting new standards in personalized cancer care.

Overview of report findings

Market Growth

The Cancer Targeted Therapy Market is projected to grow from US$ 95.12 Billion in 2024 to US$ 235.68 billion by 2031, registering a compound annual growth rate (CAGR) of 13.84% between 2025 and 2031.

The strong pipeline of monoclonal antibodies and shift towards precision medicine are key factors propelling market growth. Advancements in genomic profiling are transforming the landscape of cancer targeted therapy.

Strong Pipeline of Monoclonal Antibodies

The strong pipeline of monoclonal antibodies is a major force driving the growth of the cancer targeted therapy market, as these biologics have become central to precision oncology by offering highly specific mechanisms of action against cancer cells. Monoclonal antibodies are engineered to recognize and bind to particular antigens expressed on tumor cells, enabling targeted destruction while sparing healthy tissues, which reduces toxicity compared to traditional chemotherapy. The pipeline is robust, with numerous candidates in late‑stage clinical trials addressing a wide range of cancers including breast, lung, colorectal, and hematologic malignancies. Innovations such as antibody‑drug conjugates (ADCs), bispecific antibodies, and checkpoint inhibitors are expanding the therapeutic potential of this class, allowing for more effective treatment strategies and combination regimens. Pharmaceutical companies are investing heavily in research and development, supported by advances in genomic profiling and biomarker discovery that identify new molecular targets. Regulatory agencies are also accelerating approvals for breakthrough monoclonal antibody therapies, further boosting market momentum. As these therapies continue to demonstrate improved survival rates and better patient outcomes, their adoption is increasing globally. Collectively, the expanding pipeline of monoclonal antibodies is reshaping the cancer targeted therapy landscape, ensuring sustained growth and innovation in oncology care.

Shift Toward Precision Medicine

The global cancer targeted therapy market is being profoundly shaped by the shift toward precision medicine, which emphasizes tailoring treatments to the unique genetic and molecular profile of each patient’s tumor. Unlike traditional one‑size‑fits‑all chemotherapy, precision medicine relies on genomic profiling, biomarker discovery, and advanced diagnostic tools to identify specific mutations or pathways driving cancer growth. This approach has accelerated the development and adoption of targeted therapies such as monoclonal antibodies, tyrosine kinase inhibitors, and immune checkpoint inhibitors, which deliver more effective outcomes with fewer side effects compared to conventional treatments. The ability to match therapies to individual patients not only improves survival rates but also reduces unnecessary exposure to toxic drugs, enhancing quality of life. Precision medicine is also driving innovation in companion diagnostics, which guide treatment decisions and monitor response, creating a more integrated ecosystem of personalized care. Furthermore, the rise of tumor‑agnostic therapies—drugs approved based on genetic mutations rather than cancer type—illustrates how precision medicine is expanding the scope of targeted therapy. As healthcare systems worldwide invest in genomic testing and digital health infrastructure, the precision medicine approach is expected to remain a central driver of growth, transforming cancer care and fuelling demand for advanced targeted therapies.

Geographic Insights

North America represents the largest region in the cancer targeted therapy market, primarily due to its advanced healthcare infrastructure, strong presence of leading pharmaceutical companies, and high adoption of precision medicine supported by widespread access to genomic profiling and biomarker testing. Favourable reimbursement policies, significant research and development investments, and a large patient base with high cancer incidence further reinforce its dominance. Europe stands as the second largest region, driven by universal healthcare systems, stringent regulatory frameworks that ensure patient safety, and a growing emphasis on innovative therapies through collaborative research initiatives across countries. The region’s aging population and rising prevalence of chronic diseases also contribute to steady demand for targeted therapies, while government support for oncology programs sustains market growth. Asia Pacific, meanwhile, is the fastest growing region, fuelled by rapid healthcare infrastructure development, expanding medical tourism, and increasing awareness of advanced cancer treatments. Large patient populations in countries such as China and India, coupled with government initiatives to modernize hospitals and improve access to oncology care, are accelerating adoption. Additionally, cost‑effective manufacturing capabilities and rising investments from global pharmaceutical companies are making targeted therapies more accessible, positioning Asia Pacific as the most dynamic region in the global cancer targeted therapy market.

Market Segmentation

• Based on Therapy Type, the market is segmented into monoclonal antibodies, tyrosine kinase inhibitors, immune checkpoint inhibitors, cancer vaccines, gene therapy, and others. The monoclonal antibodies segment dominated the market in 2024.
• Based on Indication, the market is segmented into blood cancer, lung cancer, breast cancer, colorectum cancer, prostate cancer, stomach cancer, cervical cancer, liver and intrahepatic bile duct cancer, thyroid cancer, and other indications. The lung cancer segment dominated the market in 2024.

• Based on Distribution Channel, the market is segmented into hospital pharmacies, retail pharmacies, and online stores. The hospitals pharmacies dominated the market in 2024.

Competitive Strategy & Development

Key Players: The Cancer Targeted Therapy Market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Astellas Pharma Inc
2. Eli Lilly and Co
3. Novartis AG
4. Merck KGaA
5. Johnson & Johnson
6. AstraZeneca
7. Pfizer Inc

Trending Topics: Precision oncology, Biomarker-driven drug development, Combination therapies with immuno-oncology agents, Tumor-agnostic approvals, Liquid biopsy integration, Next-generation sequencing adoption, Antibody-drug conjugates (ADCs), Bispecific antibodies, CAR-T and gene-modified cell therapies, Nanotechnology-based drug delivery, AI-driven drug discovery, personalized dosing strategies, Resistance mechanism research, Expansion into rare cancers, Radiopharmaceutical-targeted therapies, Companion diagnostics growth, Real-world evidence utilization, Digital health integration in oncology, Microbiome-targeted therapies, Value-based oncology care

Global Headlines

• " Cancer Therapies Break New Ground in India with Targeted Approvals - In December 2025, India’s oncology landscape is undergoing a transformative shift as targeted therapies gain prominence over traditional chemotherapy-led models. The country has recently witnessed regulatory approvals for advanced immunotherapies, antibody-drug conjugates (ADCs), and next-generation tyrosine kinase inhibitors, marking a significant milestone in precision medicine adoption. These therapies are designed to act on specific molecular targets, offering improved efficacy and reduced toxicity compared to conventional treatments. With India facing a high burden of cancers such as lung, breast, and colorectal, the availability of these innovative drugs is expected to enhance patient outcomes and broaden treatment options."
• " A Year of Advancements in the Treatment of Cancer Highlights Targeted Therapies - In December 2025, the year 2025 marked a pivotal moment in oncology, with several landmark approvals underscoring the growing dominance of targeted therapies in cancer treatment. Johnson & Johnson’s Rybrevant gained expanded use in non‑small cell lung cancer (NSCLC), offering new hope for patients with EGFR exon 20 insertion mutations, a subgroup historically resistant to standard therapies. AstraZeneca strengthened its lung cancer portfolio with approvals for Imfinzi and Tagrisso, both of which demonstrated significant survival benefits in clinical trials and highlighted the importance of combining targeted agents with immunotherapies to improve outcomes."

Conclusion

The cancer targeted therapy market is poised for sustained expansion, driven by a convergence of scientific innovation, clinical demand, and strategic investment. Advancements in genomic profiling and biomarker discovery have revolutionized oncology by enabling precision medicine approaches that tailor treatments to individual tumor characteristics. This shift has fuelled a robust pipeline of monoclonal antibodies and small molecule inhibitors, which continue to dominate therapeutic development. A notable future trend is the rise of combination therapies that integrate targeted agents with immuno-oncology drugs, offering synergistic benefits and improved patient outcomes across multiple cancer types. Despite these promising developments, the market faces notable restraints, particularly the high cost of equipment, training, and therapy itself, which can limit accessibility in resource-constrained settings. However, these challenges are counterbalanced by significant opportunities, especially in expanding targeted therapies into rare cancers and genetically driven tumors. As research uncovers more actionable mutations and resistance mechanisms, the scope of targeted therapy is broadening beyond traditional indications. Additionally, the integration of artificial intelligence and real-world data into drug development and clinical decision-making is expected to accelerate innovation and optimize treatment pathways. In conclusion, the cancer targeted therapy market is evolving rapidly, shaped by technological progress, clinical necessity, and a growing emphasis on personalized care. Stakeholders who invest in scalable innovation and equitable access will be best positioned to lead in this dynamic and transformative landscape.